KPV
A powerful anti-inflammatory tripeptide derived from alpha-MSH for gut and immune health
KPV is one of the most elegant peptides in the immune and gut health space. It is a tripeptide, meaning it is only three amino acids long: Lysine-Proline-Valine. Despite being tiny, it packs a remarkable anti-inflammatory punch. KPV is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone your body naturally produces to regulate inflammation. KPV is the smallest piece of that hormone that still retains the full anti-inflammatory activity, without the tanning or pigmentation effects of full-length alpha-MSH.
Mechanism of action
KPV enters intestinal epithelial cells through a dedicated transport channel called PepT1. This is a peptide transporter that already exists in your gut lining specifically to absorb small peptides from digested food. Once inside the cell, KPV inhibits NF-kB nuclear translocation, which is essentially the master switch for inflammatory gene expression. The result is a significant reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-8) locally in the colon. Critically, KPV does NOT activate melanocortin receptors, meaning no tanning or pigmentation effects.
Benefits discussed in research
- Potent anti-inflammatory effects (NF-kB inhibition)
- Reduces gut inflammation in colitis models
- Calms reactive and inflamed skin conditions
- Supports intestinal barrier integrity
- Modulates immune response without immunosuppression
- Minimal systemic absorption (acts locally in the gut)
Research status
Preclinical
Dosing information
For educational and research purposes only. Not medical advice.
- typical
- 250-500 mcg once daily
- range
- 200-750 mcg/day
- frequency
- Once daily
- route
- Subcutaneous injection or oral capsule (for gut-specific targeting)
- cycleLength
- 4-8 weeks on, 2-4 weeks off
- notes
- For gut health applications, oral administration may be preferred as KPV is absorbed via the PepT1 transporter in intestinal cells, delivering it directly where it is needed. Often combined with BPC-157 for a dual anti-inflammatory plus repair approach.
Reconstitution and storage
Remove the caps from the bacteriostatic water and KPV vial. Clean both stoppers with alcohol swabs. Draw 200 units (2 mL) of bacteriostatic water into a syringe and inject slowly into the KPV vial. Gently swirl until fully dissolved. The solution is now 2.5 mg/mL (2,500 mcg/mL).
Lyophilized powder: store in a cool, dry place away from light. Once reconstituted: refrigerate at 2-8C and use within 30 days.
Side effects and safety
- Generally very well tolerated
- Mild injection site irritation (rare)
- No significant side effects reported in preclinical studies
- Does not cause tanning or pigmentation (unlike full alpha-MSH)
Frequently asked questions
What is KPV derived from?
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Your body naturally produces alpha-MSH to regulate inflammation. KPV is the smallest piece of that hormone that still retains the full anti-inflammatory activity.
Does KPV cause tanning or skin darkening?
No. Unlike full-length alpha-MSH or melanotan, KPV does not activate melanocortin receptors. It is purely anti-inflammatory with no pigmentation effects.
Can I take KPV orally for gut issues?
Yes. KPV is absorbed via the PepT1 transporter in intestinal epithelial cells, making oral delivery effective for gut-specific targeting. This is actually one of the advantages of KPV for gut health, as it reaches the intestinal lining directly without needing systemic absorption.
How does KPV compare to BPC-157 for gut health?
They work on different parts of the healing cycle. KPV calms the inflammatory fire (stops the damage), while BPC-157 accelerates physical tissue repair (rebuilds what was damaged). Many protocols combine both for a dual anti-inflammatory plus repair approach.
Is KPV FDA approved?
No. KPV is a research compound with no FDA approval for human use. The preclinical evidence is strong (particularly the Dalmasso 2008 study showing 60-70% reduction in gut inflammation markers), but no human randomized controlled trials have been published as of July 2026.
Research references
- PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (2008)
- Alpha-MSH Related Peptides: Anti-Inflammatory and Immunomodulating Drugs (2007)
- KPV Neuropeptide in Inflammatory Bowel Disease (2008)
Related peptides
- Thymosin Alpha-1
A thymus-derived peptide for immune modulation and antiviral defense
- LL-37
A natural antimicrobial peptide with broad-spectrum immune defense
- Thymalin
A thymus-derived peptide that restores immune function and supports longevity
- VIP
Potent anti-inflammatory neuropeptide studied for POTS, MCAS, and immune modulation